<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526460</url>
  </required_header>
  <id_info>
    <org_study_id>STATIPLAT</org_study_id>
    <nct_id>NCT01526460</nct_id>
  </id_info>
  <brief_title>Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention</brief_title>
  <acronym>STATIPLAT</acronym>
  <official_title>Prospective, Randomized, Single Center, Open Label Study Designed to Evaluate the Effect on Platelet Reactivity in Response to High Doses of Atorvastatin or Rosuvastatin Administered Before Percutaneous Coronary Intervention (PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of a loading dose of two different&#xD;
      statins on platelet reactivity (atorvastatin, metabolized by CYP3A4, and rosuvastatin, which&#xD;
      is rather independent of this enzyme)in patients at least 5 days in therapy with aspirin and&#xD;
      clopidogrel (with or without an undergoing treatment with statins) undergoing PCI for&#xD;
      coronary disease with chronic stable angina and/or evidence of inducible myocardial ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An initial assessment of platelet reactivity in response to the TRAP (thrombin receptor&#xD;
      agonist), ADP and arachidonic acid (respectively, indicative of the response to clopidogrel&#xD;
      and aspirin) will be performed with impedance aggregometry (MultiplateÂ® analyzer system).&#xD;
      Patients with a increased residual platelet reactivity to ADP test (AUC &gt; 47) will receive a&#xD;
      different antiplatelet therapy and will then be excluded from the study, the other will be&#xD;
      randomized to 3 groups of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Aggregation Curve (AUC) measured with the Multiplate 5.0 Analyzer</measure>
    <time_frame>Evaluation of platelet reactivity (in terms of AUC) two time points.</time_frame>
    <description>Evaluation of the effect of a loading dose (LD) of two different statins on platelet reactivity (atorvastatin and rosuvastatin) in terms of difference between AUC value before statin LD and after 12 hrs statin LD. The Area Under the Aggregation Curve (AUC) will be measured with the Multiplate 5.0 system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of periprocedural myocardial infarction</measure>
    <time_frame>CK and CK-MB evaluated before the procedure and two time points up to 12 hours</time_frame>
    <description>To evaluate if the loading dose of statin prevent the periprocedural myocardial damage measured by CK and CK-MB The measurments will be done once before the procedure and at 6 and 12 hours after.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Platelet Dysfunction</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No statin loading dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No statin loading dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>TORVAST</other_name>
    <other_name>TOTALIP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>40 mg</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>CRESTOR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>no statin loading dose</description>
    <arm_group_label>No statin loading dose</arm_group_label>
    <other_name>NO STATIN DRUGS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-75 years&#xD;
&#xD;
          -  Patients with chronic stable angina&#xD;
&#xD;
          -  Patients with coronary artery disease or with de novo stent restenosis of native&#xD;
             vessels.&#xD;
&#xD;
          -  Patients who are able to understand the significance of this study and to adhere to&#xD;
             recruitment by signing the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute Coronary Syndromes with an enzymatic movement (STEMI, NSTEMI).&#xD;
&#xD;
          -  Allergy or intolerance to atorvastatin, rosuvastatin, aspirin, clopidogrel.&#xD;
&#xD;
          -  Altered basal level of transaminase or CPK.&#xD;
&#xD;
          -  Patient with history of hepatitis-acute/chronic.&#xD;
&#xD;
          -  Patients already receiving high-dose statins.&#xD;
&#xD;
          -  Contraindications to antiplatelet therapy.&#xD;
&#xD;
          -  Patients with acute inflammatory disease and/or underlying chronic (hepatitis,&#xD;
             pneumonia, urinary tract, rectum ulcerative colitis etc.).&#xD;
&#xD;
          -  Patients with anemia (haemoglobin &lt;8.5 mg/dl), leukocytosis (WBC&gt; 12.000 mm3),&#xD;
             leukopenia (WBC &lt;3000 mm3), platelet count &lt;100.000; hypersplenism.&#xD;
&#xD;
          -  Patients with malignant disease.&#xD;
&#xD;
          -  Patients enrolled in other studies not yet completed.&#xD;
&#xD;
          -  Patients with known allergy / intolerance to statins.&#xD;
&#xD;
          -  Pregnant women and women who are breastfeeding.&#xD;
&#xD;
          -  Patients with myopathy (muscle pain and unexplained repeated)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Colombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele Monte Tabor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS San Raffaele Monte Tabor</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Antonio Colombo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Platelet</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Multiplate</keyword>
  <keyword>reactivity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

